Click for best price
Squamous NonSmall Cell Lung Cancer Therapeutics Market Size, Share 2022
This report contains market size and forecasts of Squamous Non-Small Cell Lung Cancer Therapeutics in Global, including the following market information:
Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Squamous Non-Small Cell Lung Cancer Therapeutics market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
BMS-906024 Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Squamous Non-Small Cell Lung Cancer Therapeutics include Ascenta Therapeutics, Inc., AstraZeneca Plc, AVEO Pharmaceuticals, Inc., Bayer AG, BIND Therapeutics, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company and F. Hoffmann-La Roche Ltd., etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Squamous Non-Small Cell Lung Cancer Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Squamous Non-Small Cell Lung Cancer Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Segment Percentages, by Type, 2021 (%)
BMS-906024
Buparlisib Hydrochloride
FP-1039
Ipilimumab
JNJ-42756493
Lenvatinib
Others
Global Squamous Non-Small Cell Lung Cancer Therapeutics Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Segment Percentages, by Application, 2021 (%)
Research Center
Hospital
Clinic
Global Squamous Non-Small Cell Lung Cancer Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Squamous Non-Small Cell Lung Cancer Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Squamous Non-Small Cell Lung Cancer Therapeutics revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Ascenta Therapeutics, Inc.
AstraZeneca Plc
AVEO Pharmaceuticals, Inc.
Bayer AG
BIND Therapeutics, Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Five Prime Therapeutics, Inc.
Genentech, Inc.
Incyte Corporation
Johnson & Johnson
MacroGenics, Inc.
Novartis AG
Oncogenex Pharmaceuticals, Inc.
PsiOxus Therapeutics Limited
| Report Attributes |
Report Details |
| Report Title |
Squamous Non-Small Cell Lung Cancer Therapeutics Market, Global Outlook and Forecast 2022-2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
107 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Squamous Non-Small Cell Lung Cancer Therapeutics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Overall Market Size
2.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size: 2021 VS 2028
2.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Squamous Non-Small Cell Lung Cancer Therapeutics Players in Global Market
3.2 Top Global Squamous Non-Small Cell Lung Cancer Therapeutics Companies Ranked by Revenue
3.3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Squamous Non-Small Cell Lung Cancer Therapeutics Companies in Global Market, by Revenue in 2021
3.5 Global Companies Squamous Non-Small Cell Lung Cancer Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Squamous Non-Small Cell Lung Cancer Therapeutics Players in Global Market
3.6.1 List of Global Tier 1 Squamous Non-Small Cell Lung Cancer Therapeutics Companies
3.6.2 List of Global Tier 2 and Tier 3 Squamous Non-Small Cell Lung Cancer Therapeutics Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Markets, 2021 & 2028
4.1.2 BMS-906024
4.1.3 Buparlisib Hydrochloride
4.1.4 FP-1039
4.1.5 Ipilimumab
4.1.6 JNJ-42756493
4.1.7 Lenvatinib
4.1.8 Others
4.2 By Type - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue & Forecasts
4.2.1 By Type - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, 2017-2022
4.2.2 By Type - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, 2023-2028
4.2.3 By Type - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2021 & 2028
5.1.2 Research Center
5.1.3 Hospital
5.1.4 Clinic
5.2 By Application - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue & Forecasts
5.2.1 By Application - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, 2017-2022
5.2.2 By Application - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, 2023-2028
5.2.3 By Application - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2021 & 2028
6.2 By Region - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue & Forecasts
6.2.1 By Region - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, 2017-2022
6.2.2 By Region - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, 2023-2028
6.2.3 By Region - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, 2017-2028
6.3.2 US Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2017-2028
6.3.3 Canada Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2017-2028
6.3.4 Mexico Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, 2017-2028
6.4.2 Germany Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2017-2028
6.4.3 France Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2017-2028
6.4.4 U.K. Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2017-2028
6.4.5 Italy Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2017-2028
6.4.6 Russia Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2017-2028
6.4.7 Nordic Countries Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2017-2028
6.4.8 Benelux Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, 2017-2028
6.5.2 China Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2017-2028
6.5.3 Japan Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2017-2028
6.5.4 South Korea Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2017-2028
6.5.5 Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2017-2028
6.5.6 India Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, 2017-2028
6.6.2 Brazil Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2017-2028
6.6.3 Argentina Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, 2017-2028
6.7.2 Turkey Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2017-2028
6.7.3 Israel Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2017-2028
6.7.4 Saudi Arabia Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2017-2028
6.7.5 UAE Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2017-2028
7 Players Profiles
7.1 Ascenta Therapeutics, Inc.
7.1.1 Ascenta Therapeutics, Inc. Corporate Summary
7.1.2 Ascenta Therapeutics, Inc. Business Overview
7.1.3 Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.1.4 Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2017-2022)
7.1.5 Ascenta Therapeutics, Inc. Key News
7.2 AstraZeneca Plc
7.2.1 AstraZeneca Plc Corporate Summary
7.2.2 AstraZeneca Plc Business Overview
7.2.3 AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.2.4 AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2017-2022)
7.2.5 AstraZeneca Plc Key News
7.3 AVEO Pharmaceuticals, Inc.
7.3.1 AVEO Pharmaceuticals, Inc. Corporate Summary
7.3.2 AVEO Pharmaceuticals, Inc. Business Overview
7.3.3 AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.3.4 AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2017-2022)
7.3.5 AVEO Pharmaceuticals, Inc. Key News
7.4 Bayer AG
7.4.1 Bayer AG Corporate Summary
7.4.2 Bayer AG Business Overview
7.4.3 Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.4.4 Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2017-2022)
7.4.5 Bayer AG Key News
7.5 BIND Therapeutics, Inc.
7.5.1 BIND Therapeutics, Inc. Corporate Summary
7.5.2 BIND Therapeutics, Inc. Business Overview
7.5.3 BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.5.4 BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2017-2022)
7.5.5 BIND Therapeutics, Inc. Key News
7.6 Boehringer Ingelheim GmbH
7.6.1 Boehringer Ingelheim GmbH Corporate Summary
7.6.2 Boehringer Ingelheim GmbH Business Overview
7.6.3 Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.6.4 Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2017-2022)
7.6.5 Boehringer Ingelheim GmbH Key News
7.7 Bristol-Myers Squibb Company
7.7.1 Bristol-Myers Squibb Company Corporate Summary
7.7.2 Bristol-Myers Squibb Company Business Overview
7.7.3 Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.7.4 Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2017-2022)
7.7.5 Bristol-Myers Squibb Company Key News
7.8 Eli Lilly and Company
7.8.1 Eli Lilly and Company Corporate Summary
7.8.2 Eli Lilly and Company Business Overview
7.8.3 Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.8.4 Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2017-2022)
7.8.5 Eli Lilly and Company Key News
7.9 F. Hoffmann-La Roche Ltd.
7.9.1 F. Hoffmann-La Roche Ltd. Corporate Summary
7.9.2 F. Hoffmann-La Roche Ltd. Business Overview
7.9.3 F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.9.4 F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2017-2022)
7.9.5 F. Hoffmann-La Roche Ltd. Key News
7.10 Five Prime Therapeutics, Inc.
7.10.1 Five Prime Therapeutics, Inc. Corporate Summary
7.10.2 Five Prime Therapeutics, Inc. Business Overview
7.10.3 Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.10.4 Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2017-2022)
7.10.5 Five Prime Therapeutics, Inc. Key News
7.11 Genentech, Inc.
7.11.1 Genentech, Inc. Corporate Summary
7.11.2 Genentech, Inc. Business Overview
7.11.3 Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.11.4 Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2017-2022)
7.11.5 Genentech, Inc. Key News
7.12 Incyte Corporation
7.12.1 Incyte Corporation Corporate Summary
7.12.2 Incyte Corporation Business Overview
7.12.3 Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.12.4 Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2017-2022)
7.12.5 Incyte Corporation Key News
7.13 Johnson & Johnson
7.13.1 Johnson & Johnson Corporate Summary
7.13.2 Johnson & Johnson Business Overview
7.13.3 Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.13.4 Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2017-2022)
7.13.5 Johnson & Johnson Key News
7.14 MacroGenics, Inc.
7.14.1 MacroGenics, Inc. Corporate Summary
7.14.2 MacroGenics, Inc. Business Overview
7.14.3 MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.14.4 MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2017-2022)
7.14.5 MacroGenics, Inc. Key News
7.15 Novartis AG
7.15.1 Novartis AG Corporate Summary
7.15.2 Novartis AG Business Overview
7.15.3 Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.15.4 Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2017-2022)
7.15.5 Novartis AG Key News
7.16 Oncogenex Pharmaceuticals, Inc.
7.16.1 Oncogenex Pharmaceuticals, Inc. Corporate Summary
7.16.2 Oncogenex Pharmaceuticals, Inc. Business Overview
7.16.3 Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.16.4 Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2017-2022)
7.16.5 Oncogenex Pharmaceuticals, Inc. Key News
7.17 PsiOxus Therapeutics Limited
7.17.1 PsiOxus Therapeutics Limited Corporate Summary
7.17.2 PsiOxus Therapeutics Limited Business Overview
7.17.3 PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.17.4 PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2017-2022)
7.17.5 PsiOxus Therapeutics Limited Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Squamous Non-Small Cell Lung Cancer Therapeutics Market Opportunities & Trends in Global Market
Table 2. Squamous Non-Small Cell Lung Cancer Therapeutics Market Drivers in Global Market
Table 3. Squamous Non-Small Cell Lung Cancer Therapeutics Market Restraints in Global Market
Table 4. Key Players of Squamous Non-Small Cell Lung Cancer Therapeutics in Global Market
Table 5. Top Squamous Non-Small Cell Lung Cancer Therapeutics Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Share by Companies, 2017-2022
Table 8. Global Companies Squamous Non-Small Cell Lung Cancer Therapeutics Product Type
Table 9. List of Global Tier 1 Squamous Non-Small Cell Lung Cancer Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Squamous Non-Small Cell Lung Cancer Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type ? Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application ? Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region ? Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2023-2028
Table 30. Ascenta Therapeutics, Inc. Corporate Summary
Table 31. Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 32. Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 33. AstraZeneca Plc Corporate Summary
Table 34. AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 35. AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 36. AVEO Pharmaceuticals, Inc. Corporate Summary
Table 37. AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 38. AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 39. Bayer AG Corporate Summary
Table 40. Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 41. Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 42. BIND Therapeutics, Inc. Corporate Summary
Table 43. BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 44. BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 45. Boehringer Ingelheim GmbH Corporate Summary
Table 46. Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 47. Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 48. Bristol-Myers Squibb Company Corporate Summary
Table 49. Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 50. Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 51. Eli Lilly and Company Corporate Summary
Table 52. Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 53. Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 54. F. Hoffmann-La Roche Ltd. Corporate Summary
Table 55. F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 56. F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 57. Five Prime Therapeutics, Inc. Corporate Summary
Table 58. Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 59. Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 60. Genentech, Inc. Corporate Summary
Table 61. Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 62. Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 63. Incyte Corporation Corporate Summary
Table 64. Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 65. Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 66. Johnson & Johnson Corporate Summary
Table 67. Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 68. Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 69. MacroGenics, Inc. Corporate Summary
Table 70. MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 71. MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 72. Novartis AG Corporate Summary
Table 73. Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 74. Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 75. Oncogenex Pharmaceuticals, Inc. Corporate Summary
Table 76. Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 77. Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 78. PsiOxus Therapeutics Limited Corporate Summary
Table 79. PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 80. PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
List of Figures
Figure 1. Squamous Non-Small Cell Lung Cancer Therapeutics Segment by Type in 2021
Figure 2. Squamous Non-Small Cell Lung Cancer Therapeutics Segment by Application in 2021
Figure 3. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in 2021
Figure 8. By Type - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 9. By Application - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 10. By Region - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 11. By Country - North America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 12. US Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 16. Germany Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 17. France Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 24. China Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 28. India Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 30. Brazil Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 33. Turkey Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 37. Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 50. MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 51. Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 52. Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 53. PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
